Chargement en cours...
Efficacy of the New Neuraminidase Inhibitor CS-8958 against H5N1 Influenza Viruses
Currently, two neuraminidase (NA) inhibitors, oseltamivir and zanamivir, which must be administrated twice daily for 5 days for maximum therapeutic effect, are licensed for the treatment of influenza. However, oseltamivir-resistant mutants of seasonal H1N1 and highly pathogenic H5N1 avian influenza...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Public Library of Science
2010
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2829070/ https://ncbi.nlm.nih.gov/pubmed/20195462 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.ppat.1000786 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|